Recurrent Oropharyngeal Cancer Completed Phase 1 / 2 Trials for Fludeoxyglucose (18F) (DB09502)

Also known as: Oropharyngeal cancer recurrent

IndicationStatusPhase
DBCOND0062581 (Recurrent Oropharyngeal Cancer)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT0180667518F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis TherapyDiagnostic